NDAINTRAVENOUSSOLUTION
Approved
May 2022
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
15
Data completeness
2/8 — Basic
Drug data last refreshed 10h ago · AI intelligence enriched 6d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Pemetrexed disodium is a folate antagonist antimetabolite administered intravenously as a lyophilized solution. It inhibits multiple enzymes involved in folate metabolism, disrupting DNA and RNA synthesis in cancer cells. The drug is indicated for malignant pleural mesothelioma and non-small cell lung cancer, typically administered in combination with cisplatin or as maintenance therapy.
Peak
Peak-stage product with moderate competitive pressure (30%) suggests stable, mature team structure focused on market maintenance and physician relationships.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (15)
Pemetrexed Disodium and Hsp90 Inhibitor AUY922 in Treating Patients With Previously Treated Stage IV Non-Small Cell Lung Cancer
Started Jan 2014
13 enrolled
Recurrent Non-small Cell Lung CancerSquamous Cell Lung CancerStage IV Non-small Cell Lung Cancer
Pemetrexed Disodium/Observation in Treating Patients W/ Malignant Pleural Mesothelioma w/Out Progressive Disease After 1st Line Chemotherapy
Started Apr 2010
72 enrolled
Malignant Mesothelioma
Gemcitabine Hydrochloride or Pemetrexed Disodium and Carboplatin With or Without Celecoxib in Treating Patients With Advanced Non-Small Cell Lung Cancer
Started Feb 2010
313 enrolled
Lung Cancer
Pemetrexed Disodium With or Without Sorafenib as Second-Line Therapy in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer
Started Sep 2007
110 enrolled
Lung Cancer
Gemcitabine and Pemetrexed Disodium in Treating Patients With Advanced Mycosis Fungoides or Sézary Syndrome
Started Aug 2006
14 enrolled
Lymphoma
Worked on PEMETREXED DISODIUM at Novartis? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.